Cargando…
Role of HIPEC after Complete Cytoreductive Surgery (CRS) in Peritoneal Recurrence of Platinum-Sensitive Recurrent Ovarian Cancer (OC): The Aim for Standardization at Two Reference Centers for CRS
SIMPLE SUMMARY: The vast majority of patients with epithelial ovarian carcinoma (OC) will relapse during the natural history of their disease. The role of cytoreductive surgery (CRS) in the treatment of recurrent disease has been emphasized by current studies. Adding hyperthermic intraperitoneal che...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856919/ https://www.ncbi.nlm.nih.gov/pubmed/36672352 http://dx.doi.org/10.3390/cancers15020405 |
_version_ | 1784873747006619648 |
---|---|
author | Acs, Miklos Gerken, Michael Schmitt, Vanessa Piso, Pompiliu Königsrainer, Alfred Baransi, Saher Yurttas, Can Häusler, Sebastian Horvath, Philipp |
author_facet | Acs, Miklos Gerken, Michael Schmitt, Vanessa Piso, Pompiliu Königsrainer, Alfred Baransi, Saher Yurttas, Can Häusler, Sebastian Horvath, Philipp |
author_sort | Acs, Miklos |
collection | PubMed |
description | SIMPLE SUMMARY: The vast majority of patients with epithelial ovarian carcinoma (OC) will relapse during the natural history of their disease. The role of cytoreductive surgery (CRS) in the treatment of recurrent disease has been emphasized by current studies. Adding hyperthermic intraperitoneal chemotherapy (HIPEC) has been evolved to improve DFS and OS. There are currently two convincing studies of HIPEC after complete cytoreduction in the treatment of primary OC, but there is little homogenous data on the role of HIPEC in platinum-sensitive recurrent ovarian cancer, its ideal compound, and its duration. The aim of this study was to analyze the bicentric experience with CRS + HIPEC in patients with platinum-sensitive recurrent epithelial OC in order to standardize the surgical approach. Thus, multimodal therapy was feasible with acceptable morbidity and mortality. Cisplatin monotherapy as a HIPEC compound and a 90 min HIPEC application proved to be the best option for regional additive treatment. ABSTRACT: Background: This bicentric study evaluated cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for platinum-sensitive recurrent ovarian cancer patients. Methods: The data of 88 patients with the first peritoneal recurrence of platinum-sensitive epithelial ovarian cancer who underwent CRS and HIPEC from a prospective HIPEC registry were retrospectively investigated. Endpoints were feasibility, chemotherapeutic compound, time of exposure, complications, and overall survival. Results: The median follow-up was 4.7 years (95%-CI 4.6–5.5). The median age was 55.8 years (IQR: 50.3–66.2). Eighty-four patients (95.5%) had high-grade serous histology. The median peritoneal cancer index was 12.0 (IQR: 7.0–20.5). Sixty-five patients (73.9%) had complete cytoreduction (CCR 0). Thirty-eight patients (43.2%) received HIPEC for 60 min, and fifty patients (56.8%) for 90 min. Eighteen patients (20.5%) had grade III to IV complications. One patient (1.1%) died perioperatively. The overall median survival was 43.1 months (95%-CI 34.1–52.2), and the 5-year survival rate was 39.7%. Only 90 min HIPEC and cisplatin were associated with survival. Conclusion: In well-selected patients with platinum-sensitive recurrent ovarian cancer, survival may correlate with complete CRS and 90 min cisplatin-based HIPEC. We confirmed the results of primary OC studies; therefore, this combination should be used for further analysis in the recurrent situation. |
format | Online Article Text |
id | pubmed-9856919 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98569192023-01-21 Role of HIPEC after Complete Cytoreductive Surgery (CRS) in Peritoneal Recurrence of Platinum-Sensitive Recurrent Ovarian Cancer (OC): The Aim for Standardization at Two Reference Centers for CRS Acs, Miklos Gerken, Michael Schmitt, Vanessa Piso, Pompiliu Königsrainer, Alfred Baransi, Saher Yurttas, Can Häusler, Sebastian Horvath, Philipp Cancers (Basel) Article SIMPLE SUMMARY: The vast majority of patients with epithelial ovarian carcinoma (OC) will relapse during the natural history of their disease. The role of cytoreductive surgery (CRS) in the treatment of recurrent disease has been emphasized by current studies. Adding hyperthermic intraperitoneal chemotherapy (HIPEC) has been evolved to improve DFS and OS. There are currently two convincing studies of HIPEC after complete cytoreduction in the treatment of primary OC, but there is little homogenous data on the role of HIPEC in platinum-sensitive recurrent ovarian cancer, its ideal compound, and its duration. The aim of this study was to analyze the bicentric experience with CRS + HIPEC in patients with platinum-sensitive recurrent epithelial OC in order to standardize the surgical approach. Thus, multimodal therapy was feasible with acceptable morbidity and mortality. Cisplatin monotherapy as a HIPEC compound and a 90 min HIPEC application proved to be the best option for regional additive treatment. ABSTRACT: Background: This bicentric study evaluated cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for platinum-sensitive recurrent ovarian cancer patients. Methods: The data of 88 patients with the first peritoneal recurrence of platinum-sensitive epithelial ovarian cancer who underwent CRS and HIPEC from a prospective HIPEC registry were retrospectively investigated. Endpoints were feasibility, chemotherapeutic compound, time of exposure, complications, and overall survival. Results: The median follow-up was 4.7 years (95%-CI 4.6–5.5). The median age was 55.8 years (IQR: 50.3–66.2). Eighty-four patients (95.5%) had high-grade serous histology. The median peritoneal cancer index was 12.0 (IQR: 7.0–20.5). Sixty-five patients (73.9%) had complete cytoreduction (CCR 0). Thirty-eight patients (43.2%) received HIPEC for 60 min, and fifty patients (56.8%) for 90 min. Eighteen patients (20.5%) had grade III to IV complications. One patient (1.1%) died perioperatively. The overall median survival was 43.1 months (95%-CI 34.1–52.2), and the 5-year survival rate was 39.7%. Only 90 min HIPEC and cisplatin were associated with survival. Conclusion: In well-selected patients with platinum-sensitive recurrent ovarian cancer, survival may correlate with complete CRS and 90 min cisplatin-based HIPEC. We confirmed the results of primary OC studies; therefore, this combination should be used for further analysis in the recurrent situation. MDPI 2023-01-07 /pmc/articles/PMC9856919/ /pubmed/36672352 http://dx.doi.org/10.3390/cancers15020405 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Acs, Miklos Gerken, Michael Schmitt, Vanessa Piso, Pompiliu Königsrainer, Alfred Baransi, Saher Yurttas, Can Häusler, Sebastian Horvath, Philipp Role of HIPEC after Complete Cytoreductive Surgery (CRS) in Peritoneal Recurrence of Platinum-Sensitive Recurrent Ovarian Cancer (OC): The Aim for Standardization at Two Reference Centers for CRS |
title | Role of HIPEC after Complete Cytoreductive Surgery (CRS) in Peritoneal Recurrence of Platinum-Sensitive Recurrent Ovarian Cancer (OC): The Aim for Standardization at Two Reference Centers for CRS |
title_full | Role of HIPEC after Complete Cytoreductive Surgery (CRS) in Peritoneal Recurrence of Platinum-Sensitive Recurrent Ovarian Cancer (OC): The Aim for Standardization at Two Reference Centers for CRS |
title_fullStr | Role of HIPEC after Complete Cytoreductive Surgery (CRS) in Peritoneal Recurrence of Platinum-Sensitive Recurrent Ovarian Cancer (OC): The Aim for Standardization at Two Reference Centers for CRS |
title_full_unstemmed | Role of HIPEC after Complete Cytoreductive Surgery (CRS) in Peritoneal Recurrence of Platinum-Sensitive Recurrent Ovarian Cancer (OC): The Aim for Standardization at Two Reference Centers for CRS |
title_short | Role of HIPEC after Complete Cytoreductive Surgery (CRS) in Peritoneal Recurrence of Platinum-Sensitive Recurrent Ovarian Cancer (OC): The Aim for Standardization at Two Reference Centers for CRS |
title_sort | role of hipec after complete cytoreductive surgery (crs) in peritoneal recurrence of platinum-sensitive recurrent ovarian cancer (oc): the aim for standardization at two reference centers for crs |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856919/ https://www.ncbi.nlm.nih.gov/pubmed/36672352 http://dx.doi.org/10.3390/cancers15020405 |
work_keys_str_mv | AT acsmiklos roleofhipecaftercompletecytoreductivesurgerycrsinperitonealrecurrenceofplatinumsensitiverecurrentovariancanceroctheaimforstandardizationattworeferencecentersforcrs AT gerkenmichael roleofhipecaftercompletecytoreductivesurgerycrsinperitonealrecurrenceofplatinumsensitiverecurrentovariancanceroctheaimforstandardizationattworeferencecentersforcrs AT schmittvanessa roleofhipecaftercompletecytoreductivesurgerycrsinperitonealrecurrenceofplatinumsensitiverecurrentovariancanceroctheaimforstandardizationattworeferencecentersforcrs AT pisopompiliu roleofhipecaftercompletecytoreductivesurgerycrsinperitonealrecurrenceofplatinumsensitiverecurrentovariancanceroctheaimforstandardizationattworeferencecentersforcrs AT konigsraineralfred roleofhipecaftercompletecytoreductivesurgerycrsinperitonealrecurrenceofplatinumsensitiverecurrentovariancanceroctheaimforstandardizationattworeferencecentersforcrs AT baransisaher roleofhipecaftercompletecytoreductivesurgerycrsinperitonealrecurrenceofplatinumsensitiverecurrentovariancanceroctheaimforstandardizationattworeferencecentersforcrs AT yurttascan roleofhipecaftercompletecytoreductivesurgerycrsinperitonealrecurrenceofplatinumsensitiverecurrentovariancanceroctheaimforstandardizationattworeferencecentersforcrs AT hauslersebastian roleofhipecaftercompletecytoreductivesurgerycrsinperitonealrecurrenceofplatinumsensitiverecurrentovariancanceroctheaimforstandardizationattworeferencecentersforcrs AT horvathphilipp roleofhipecaftercompletecytoreductivesurgerycrsinperitonealrecurrenceofplatinumsensitiverecurrentovariancanceroctheaimforstandardizationattworeferencecentersforcrs |